


# First-line azacitidine in advanced pediatric myelodysplastic syndrome leads to reduction or suppression of bone marrow blasts in seven of eight patients, has a favorable toxicity profile, and could improve event-free survival

👤 n=22 pediatric patients with advanced myelodysplastic syndrome

📅 diagnosed between January 2000 and December 2015



**Azacitidine-treated patients had significantly increased 4-year event-free survival (p=0.04)**

